Maternal and fetal arrhythmias occurring during pregnancy may jeopardise the life of the mother and the fetus. When arrhythmias are well tolerated and patients are minimally symptomatic, conservative therapy, such as observation and rest or vagal manoeuvres, should be employed. When arrhythmias cause debilitating symptoms or haemodynamic compromise, antiarrhythmic drug therapy is indicated. Although no antiarrhythmic drug is completely safe during pregnancy, most are well tolerated and can be given with relatively low risk.
Physiological changes that occur during pregnancy mandate caution when administering antiarrhythmic drugs, with close monitoring of serum concentration and patient response. Drug therapy should be avoided during the first trimester of pregnancy if possible, and drugs with the longest record of safety should be used as first-line therapy.
Several therapeutic options exist for most arrhythmias in the mother and fetus. Of the class IA agents, quinidine has the longest record of safety during pregnancy, and is generally well tolerated. Procainamide is also well tolerated, and should be a first line option for acute treatment of undiagnosed wide complex tachycardia. All IA agents should be administered in the hospital under cardiac monitoring due to the potential risk of ventricular arrhythmias (torsade de pointes).
The IB agent, lidocaine (lignocaine), has local anaesthetic role but is also generally well tolerated as an antiarrhythmic agents. Phenytoin should be avoided due to the high risk of congenital malformations and limited role as an antiar-rhythmic drug. Of the IC agents, flecainide has been shown to be very effective in treating fetal supraventricular tachycardia complicated by hydrops. β-Blockers are generally well tolerated and can be used with relative safety in pregnancy, although recent data suggest that they may cause intrauterine growth retardation if they are administered during the first trimester.
Amiodarone, a class II agents with characteristics of the other antiarrhythmic drug classes, has been reported to cause congenital abnormalities; it should be avoided during the first trimester and used only to treat life-threatening arrhythmias that fail to respond to other therapies. Adenosine is generally safe to use in pregnancy, and is the drug of choice for acute termination of maternal supraventricular tachycardia. Digoxin has a long track record of treating both maternal and fetal arrhythmias, and is one of the safest antiarrhythmics to use during pregnancy.
Direct current cardioversion to terminate maternal arrhythmias is well tolerated and effective, and should not be delayed if indicated. The use of an implantable cardioverter-defibrillator should be considered for women of childbearing potential with life-threatening ventricular arrhythmias.
Adis International Limited Digoxin Amiodarone Antiarrhythmic Drug Sotalol
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Saxon LA, Perloff JK. Arrhythmias and conduction disturbances associated with pregnancy. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia. Baltimore (MD): Williams & Wilkins, 1995: 1161–74Google Scholar
Ostrzega E, Mehra A, Widerhorn J, et al. Evidence of increased incidence of arrhythmias during pregnancy: a study of 104 pregnant women with symptoms of palpitations, dizziness or syncope [abstract]. J Am Coll Cardiol 1992; 19: 125ACrossRefGoogle Scholar
Widerhorn J, Widehorn ALM, Rahimtoola SH, et al. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123: 796–8PubMedCrossRefGoogle Scholar
Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risk of the offspring of women treated with hydantoin anticonvulsants with emphasis on fetal hydantoin syndrome. J Pediatr 1976; 89: 662–8PubMedCrossRefGoogle Scholar
Echt DS, Liebson PR, Mitchel B, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991; 324: 781–8PubMedCrossRefGoogle Scholar
Allan LD, Chita SK, Sharland GK, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J 1991; 65: 46–8PubMedCrossRefGoogle Scholar
Frohn-Mulder IM, Stewart PA, Witsenburg M, et al. The efficacy of flecainide versus digoxin in the management of fetal supaventricular tachycardia. Prenat Diagn 1995; 15: 1297–302PubMedCrossRefGoogle Scholar
Vanderhalt AL, Cocjin J, Santulli TV, et al. Conjugated hyprbilirubenemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. J Pediatr 1995; 126: 988–90CrossRefGoogle Scholar
Capucci A, Boriani G. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Drug Saf 1995; 12: 55–72PubMedCrossRefGoogle Scholar
Anderson, JL. Sotalol, bretylium, and other class 3 antiarrhythmics. In: Podrid PJ, Kowey PR, editors. Cardiac arrhythmia. Baltimore: Williams & Wilkins, 1995: 450-66Google Scholar
O’Hare MF, Murnaghan GA, Russell CJ, et al. Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol 1980; 87: 814–20PubMedCrossRefGoogle Scholar
Wagner X, Jouglard J, Moulin M, et al. Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human milk. Am Heart J 1990; 119: 700–2PubMedCrossRefGoogle Scholar
Kowey PR, Vander Lugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78(8a): 46–52PubMedCrossRefGoogle Scholar
Bryerly WG, Hartmann A, Foster DE, et al. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20: 552–4CrossRefGoogle Scholar
Kleinman CS, Copel JA, Weinstein EM, et al. Treatment of fetal supraventricular tachyarrhythmias. J Clin Ultrasound 1985; 13: 265–73PubMedCrossRefGoogle Scholar
Parilla B, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. Am J Perinatol 1996; 13: 483–6PubMedCrossRefGoogle Scholar
Mitani GM, Harrison EC, Steingberg I, et al. Digitalis glycosides in pregnancy. In: Elkayam U, Gleicher N, editors. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. New York: Liss, 1990: 417–27Google Scholar
Gonzalez AR, Phelps SJ, Cochran EB, et al. Digoxin-like immunoreactive substance in pregnancy. Am J Obstet Gynecol 1987; 157: 660–4PubMedGoogle Scholar